Purpose: Type 2 diabetes mellitus (T2DM) is a multifactorial disease characterized by insulin resistance. As time progresses, monotherapy often does not provide effective glycemic control, generating the need for an add-on therapy. Hence, multiple oral hypoglycemic agents formulated as a single-dose form called fixed-dose combinations (FDCs) play an essential role in glycemic control. The purpose of this systematic review is to appraise the recently published evidence on the safety, efficacy, and bioavailability of FDCs. Methods: A comprehensive literature search of PUBMED, Scopus, ScienceDirect.com, ProQuest, SpringerLink, clintrials.gov, Embase, and EBSCO using the key words FDCs, combination therapy, T2DM management, and add-on therapy was conducted. Studies on the safety profile/tolerability, efficacy, and bioavailability of various FDCs of oral hypoglycemic agents were preferred. Findings: The systematic review of all the publications suggests that FDCs of oral hypoglycemic agents (OHAs) significantly reduce HbA 1c and fasting plasma glucose values, thereby efficiently reducing hyperglycemia in patients in whom monotherapy fails. FDCs are the bioequivalent of the concomitant drugs administered as individual components. Improved adherence to FDCs and the absence of serious adverse drug reactions compared with dual therapy play an important role in decreasing the incidence of hyperglycemia in patients with T2DM.
Type 2 diabetes mellitus (T2DM) is a multifactorial disease affecting multiple organ systems. 1, 2 It is characterized by the resistance of cells to insulin, thereby causing hyperglycemia. 3 It is associated with microvascular and macrovascular complications that in the long run can lead to morbidity and mortality. 4, 5 Lifestyle modifications and monotherapy with oral hypoglycemic agents are generally considered first-line intervention for glycemic control. 5, 6 As the disease progresses, β cells continue to deteriorate in T2DM patients who require effective glycemic control. 7 Most often, the efficacy of monotherapy decreases after a few years of treatment, resulting in ineffective glycemic control, and does not prevent the progression of disease, which requires an additional agent for effective glycemic control. 8 For the successful management of both insulin resistance and β-cell dysfunction, there arises a need for combination therapy with agents having complementary mechanisms of action formulated in a single-dose form called fixed-dose combinations (FDCs).
▪ FDCs improve glycemic control, showing better efficacy.
5
▪ Medical expenditures due to hospitalization can be reduced.
28
▪ It decreases the frequency of drug administration in patients with T2DM. 29 ▪ It prevents polypharmacy. 18 
Disadvantages of FDCs
▪ Dose titration will be difficult. ▪ A patient who is satisfied taking separate medications may not switch to FDCs. ▪ There may be an increase in the number of adverse drug reactions (ADRs).
28
▪ The combination may affect the bioavailability of agents. 22 The objective of this review was to analyze the use of FDCs in glycemic control and their efficacy, safety, and bioavailability in patients with T2DM.
Material and Methods
A comprehensive literature search of PUBMED, Scopus, ScienceDirect.com, ProQuest, SpringerLink, clintrials.gov, Embase, and EBSCO using the key words FDCs, combination therapy, T2DM management, and add-on therapy was conducted. The search resulted in the collection of 128 articles. The search was narrowed down to original research articles on FDCs in T2DM. Editorial letters, reviews, case report studies that included o30 patients in the study, and articles related to studies in the special population (patients with comorbidities, pregnancy, and lactation) were excluded. The search was restricted to the articles published in English. The search on FDC therapies was concentrated on their efficacy, safety, tolerability, bioequivalence, adherence, and compliance. Of the 58 appropriate articles collected, 36 were included based on the criteria that the studies were conducted in patients with newly diagnosed T2DM and known cases of T2DM with increased fasting plasma glucose (FPG) levels, increased glycosylated hemoglobin (HbA 1c ) levels, and increased post-prandial blood sugar levels in the age group of 18 to 80 years. The articles were included irrespective of the sex and race in which the studies were conducted. The various methods used in the studies include open-label, prospective, retrospective, randomized, nonrandomized, double-blind, parallel, placebo-controlled, noninterventional, and crossover studies.
The study characteristics such as author, year of publication, type of study, population size, baseline HbA 1c , FPG values, and outcomes such as efficacy and safety of FDCs were noted and checked. The systematic review protocol is represented in Figure 1 .
Results and Discussion
The effect of FDCs in the treatment of T2DM was addressed by 9 studies, 2 of which were prospective, 1 was observational, and 7 were randomized, double-blind, parallel studies. , fasting blood glucose, and body weight were measured. The study showed that there was a significant decrease in FBG, PPG, HbA 1c , and body weight from baseline. The most common ADR was flatulence, and only 5 patients experienced hypoglycemia during the study. The physicians were asked to rate their overall satisfaction as satisfied or not satisfied and tolerability as poor, fair, good, or excellent. Of the patients, 91.8% showed excellent to good tolerance according to the physician's assessment. In conclusion, this study states that the acarbose and metformin FDC was found to be efficacious, safe, and well tolerated by the patients. However, this study has the limitation of not being placebo controlled or blinded as it was planned for postmarketing surveillance.
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A 24-week observational study performed by Rombopoulos et al 18 determine the safety and efficacy of the empagliflozin and linagliptin FDC as initial treatment in patients with T2DM. The study led to a clinically significant reduction in HbA 1c in subjects whose baseline values were Z8.5% compared with the subjects whose baseline values were r 8.5%. The combination is likely to decrease the weight of the subjects by promoting urinary glucose excretion. None of the subjects included in the study reported confirmed hypoglycemia. The combination was well tolerated, with few patients experiencing a urinary tract infections, genital infections, and hypersensitivity reactions as ADRs of mild to moderate intensity. A randomized, double-blind, parallel, 16-week multicenter clinical trial was conducted by Chien et al 16 in 2007 to evaluate the safety and efficacy of glyburide and metformin. The study reported a significant decrease in HbA 1c and FPG values (Po0.0001) in patients treated with FDCs when compared with monotherapy. Of patients in this study, 14.3% reported hypoglycemia. A higher incidence (15.4%) of nervous system side effects such as dizziness and confusion were reported in patients treated with FDCs compared with monotherapy. he study duration was too short to provide information regarding long-term safety. The article states that the combination was well tolerated with improved adherence by simplifying dosage regimen.
In the same year, a 24-week, randomized, double-blind, placebo-controlled study was conducted by Goldstein et al 12 to
evaluate the effect of the combination therapy of sitagliptin and metformin in patients with T2DM. This study also showed a significant reduction in HbA 1c with a lower incidence of hypoglycemia. The patients experienced gastrointestinal ADRs such as abdominal pain, nausea, vomiting, and diarrhea, the incidence of which was similar to the monotherapy group. In conclusion, this combination reduced hyperglycemia significantly with a tolerability profile similar to that of monotherapy with metformin. A comprehensive systematic review of all the publications suggests that FDCs of oral hypoglycemic agents significantly reduce HbA 1c and FPG values, thereby efficiently reducing hyperglycemia in patients who fail to achieve glycemic control with monotherapy. However, there are some limitations for FDCs such as difficulty in dose titration and stability problems between the drugs leading to incompatibilities. Study design, intervention, outcomes, and safety of FDC use in T2DM was shown in Table II 
Summary
The present systematic review of FDCs of various oral hypoglycemic agents suggests that these are beneficial to patients with T2DM in order to achieve their target glycemic levels by effectively controlling hyperglycemia. The review also suggests that the most widely used component of FDCs is metformin with other OHAs such as glimepiride, pioglitazone, rosiglitazone, acarbose, and sitagliptin. Studies on FDCs without metformin as one of the components were found to be fewer in number.
The pharmacokinetic studies on FDCs suggest that these drugs are bioequivalent to the individual components that are coadministered in the same doses, which in turn facilitates the formulation of a single-dose form, thereby reducing the economic burden on patients and increasing patient medication adherence. As FDCs help to reduce hyperglycemia efficiently, the long-term complications of diabetes can be minimized in these patients and thus improve the quality of life of these patients. A search restricted to English-language articles is a limitation of this review.
In conclusion, the favorable effects of FDCs and lack of increased incidence of adverse effects could play an important role in decreasing the increasing global incidence of hyperglycemia due to T2DM compared with dual therapy with individual components.
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